Loading clinical trials...
Loading clinical trials...
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
NGM Biopharmaceuticals, Inc
Collaborators
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT07660627 · Esophageal Adenocarcinoma, Gastric Cancer, and more
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT06400563 · Breast Cancer
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NGM Clinical Study Site
Gilbert, Arizona
NGM Clinical Study Site
Los Angeles, California
NGM Clinical Study Site
Sarasota, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions